Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

Non Small Cell Lung Cancer Clinical Trial

— CERTAIN  

Official title:

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in EGFR Active Mutation for the First Line Treatment of Non-Small Cell Lung Cancer at Stage IV: A Single-arm, Open-label, Single Center, Phase II Trial.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02353741
• Other study ID #: XQonc-001
• Status: Terminated
• Phase: Phase 2
• Start date: April 2015
• Est. completion date: December 1, 2018

Study information

• Verified date: December 2018
• Source: Xinqiao Hospital of Chongqing
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This single-arm phase II study aims to study the efficacy of a possible first line treatment that combines epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) with concurrent thoracic radiation therapy for stage IV non-small cell lung cancer (NSCLC) with active EGFR mutation, as well as assessing PFS, OS, tumor response, etc. to verify that this new combinational therapy can benefit short-term and long-term survival of the patients with advanced NSCLC.

Description:

Based on NCCN guideline of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) such as erlotinib, gefitinib and icotinib as the first line treatment for advanced Non-Small Cell Lung Cancer (NSCLC), the efficacy of EGFR-TKIs in combination with thoracic radiotherapy as the first line treatment for stage IV NSCLC with active EGFR mutation remains unknown. In this single-arm phase II trial, we chose the subjects with stage IV harboring active EGFR mutation,who were treated by EGFR-TKIs combined with radiation therapy. The primary endpoint is 1-year rate of progression-free survival and the second endpoints are overall survival (OS), objective response rate and toxic and side effect. By evaluating them, we expect to find out the evidence that the combination therapy can benefit the short-term and long-term survival of the patients. Meanwhile, via the stratification analysis of tumor biomarker and immune index, we obtain the evidences for the benefits of comprehensive and individual treatment for advanced NSCLC.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: December 1, 2018
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. ECOG performance status=2;

2. Cytologically or pathologically confirmed stage IV NSCLC ( controlled pleural effusion will be eligible) with active EGFR mutation;

3. Estimated survival time more than 3 months;

4. Age older than 18 years and under 75 years;

5. Adequate bone marrow, hepatic, and renal function;AST and ALT=2.5 times the highest reference value when not associated with hepatic metastases, or =5 times when hepatic metastases occur;

6. Without history of therapy for primary and metastatic disease;

7. With pleural effusion but can be controlled;

8. Asymptomatic bone metastases without treatment;

9. Based on fusion images of 4DCT MIP sketch tumors and lymph nodes, and limit the mean lung dose: V20=25%,V30=18%,MLD=14Gy,V5=60%;

10. M1a or M1b for metastases, and the number of the distant lesions =10;

11. Voluntary to participate in this clinical trial and sign the consent form.

Exclusion Criteria:

1. Patients with serious functional damage of important organs;

2. Patients diagnosed adequately with other malignant tumors;

3. Pregnant or lactating women;

4. Patients in an active period of acute or chronic infectious diseases;

5. Patients who are allergic to any drugs or people with allergies;

6. With brain metastases;

7. With bone metastases needing radiotherapy;

8. Patients who participate in other clinical trials concurrently;

9. Uncontrolled pleural effusion which may intervene the radiotherapy to primary tumor in lung;

10. The number of the distant lesions>10;

11. Patients who are considered not eligible for the trial after evaluation by investigator.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• EGFR-TKIs
Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.

Radiation:
• thoracic radiotherapy
From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54~60Gy/27~30f/5.5~6w.

Locations

Country	Name	City	State
China	Xinqiao Hospital of Chongqing	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Xinqiao Hospital of Chongqing

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1-year rate of progression-free survival	1-year rate of progression-free survival	one year after treatment, followed
Secondary	Overall survival (OS)	Overall survival (OS)	From the time of study enrollment until the date of death
Secondary	Objective response rate	Assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)	up to three years
Secondary	Disease control rate	Assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)	up to three years
Secondary	patients quality of life	Assessed by EORTC-QLQ C30	up to three years
Secondary	Failure mode	The number of patients who failed the treatment of EGFR-TKIs with thoracic radiotherapy.	up to three years
Secondary	Toxicities associated with combined erlotinib and concurrent thoracic radiotherapy. Assessed by Common Terminology Criteria for Adverse Events(CTCAE)	Assessed by Common Terminology Criteria for Adverse Events(CTCAE)	up to three years